FDA Approves New Parkinson's Add-On Drug Xadago

Share this content:
FDA Approves New Parkinson's Add-On Drug Xadago
FDA Approves New Parkinson's Add-On Drug Xadago

WEDNESDAY, March 22, 2017 (HealthDay News) -- Xadago (safinamide) tablets have been approved by the U.S. Food and Drug Administration as an add-on drug to treat Parkinson's patients who take levodopa or carbidopa but experience "off" episodes.

Xadago's effectiveness was established in a clinical study of 645 patients who were taking levodopa but were still having "off" periods. Compared to patients who took a placebo, users of Xadago had fewer instances of Parkinson's symptoms.

Certain patients shouldn't take Xadago, including those with severe liver problems and those taking dextromethorphan, monoamine oxidase inhibitors, or certain antidepressants, the FDA said.

Xadago's most common side effects included involuntary movement, falls, nausea, and insomnia. More serious adverse reactions included worsening hypertension, falling asleep during daily activities, hallucinations, psychotic and/or compulsive behavior, fever, and confusion.

The FDA granted approval of Xadago to Newron Pharmaceuticals, based in Milan.

More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Ground Beef Recalled After E. Coli Outbreak

Ground Beef Recalled After <i>E. Coli</i> Outbreak

Beef was produced and packaged at Cargill Meat Solutions in Fort Morgan, Colo.

Prevalence of Alzheimer's, Related Dementia Set to Double

Prevalence of Alzheimer's, Related Dementia Set to Double

Alzheimer's disease and related dementias burden is expected to increase to 3.3 percent in 2060

Long-Term Outcomes of Breast Implants Explored

Long-Term Outcomes of Breast Implants Explored

Higher rates of Sjogren syndrome, scleroderma, RA, stillbirth, melanoma for silicone implants

is free, fast, and customized just for you!




Already a member?

Sign In Now »